Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firsocostat + semaglutide
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
Firsocostat + semaglutide is a combination therapy being investigated for the treatment of non-alcoholic steatohepatitis (NASH). Firsocostat is an oral, liver-targeted inhibitor of acetyl-coenzyme A carboxylase (ACC), which plays a role in fatty acid synthesis. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that improves glycemic control and promotes weight loss. The combination targets multiple pathways involved in NASH pathophysiology, potentially offering more comprehensive benefits than monotherapy.
02
Targets
ACC (Acetyl-CoA Carboxylase 1)GLP1R (GLP-1R)
Beyond the preview
Go deeper on firsocostat + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firsocostat + semaglutide.